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LETTER
Mutational spectrum and
phenotypic variability of
VCP-related neurological
disease in the UK
INTRODUCTION
Hereditary inclusion body myopathy
(IBM) with Paget’s disease of the bone
(PDB) and frontotemporal dementia
(FTD) (IBMPFD) is a rare autosomal dom-
inant disorder due to mutations in the
valosin-containing protein gene (VCP).1
Pathogenic VCP variants have also been
associated with amyotrophic lateral scler-
osis2 and other phenotypes including
dilated cardiomyopathy and Parkinson’s
disease. We describe phenotypic and
genetic findings of 42 individuals from 21
families with VCP mutations. As our
service is the reference laboratory for the
UK, we calculated the UK’s point preva-
lence based on the 2011 Census as the
number of cases per population.
RESULTS
In total, 42 individuals were identified, 23
men and 19 women from 21 kinships (see
online supplementary tables S1A, B).
Based on our data, the expected point
prevalence of IBMPFD in the UK is
0.066/100 000 population.
Eighteen unrelated patients harbour a
previously described mutation. In addition,
three patients from two families harbour
two novel variants (c.604G>T, p.G202W
in exon 6 and c.1316C>G, p.A439G in
exon 11) that are predicted to be patho-
genic by in silico analysis (Alamut interpret-
ation software V.2.4) and segregate with
disease. Three previously described muta-
tions were identified in exon 5 of the VCP
gene. The mutation p.R155H (c.464G>A)
was found in 11 families. The mutation p.
R191Q (c.572G>A) was found in three
unrelated patients, p.R155C (c.463C>T)
in two families, and p.R93C (c.277C>T)
in two unrelated patients (see online supple-
mentary material genetic analysis and muta-
tion analysis).
The mean age of disease onset was
42.05±7.94 years. Three individuals were
tested as part of a family screening and
were asymptomatic at the ages of 21, 23
and 31 years.
Muscle weakness was the first manifest-
ation (figure 1) in 92.3% of patients, PDB
was the first symptom in one case, and in
two cases we were unable to obtain this
information. Proximal weakness of both
limb girdles was the presentation in 27%
of patients; 21.6% presented with prox-
imal upper limb weakness, and 13.5%
with proximal lower limb weakness. A
combination of distal and/or proximal
upper and/or lower limb weakness at
onset was seen in 24.2%. In two patients,
falls were the first reported symptom.
Twenty-three patients remained ambu-
lant after 15.7±8.2 years (range 5–39).
The mean time to loss of ambulation was
13.37±6.6 years (range 5–22 years). Of
the 10 non-ambulant patients, 6 (60%)
experienced some degree of cognitive
decline compared with 33.3% of the
ambulant patients.
Additional clinical findings (see online
supplementary table S2) were scapular
winging in 20 patients (50%), markedly
atrophic hands in 6 patients (15.4%), camp-
tocormia, or bent spine, in 6 (15.4%),
finger extensor weakness in 5 (12.8%),
facial weakness in 3 (7.7%) and weakness
of abdominal muscles in two patients
(5.1%). An asymmetric pattern of muscle
involvement was present in nine patients
(23%). Nine patients (23%) experienced
sphincter or erectile dysfunction. Two
patients were diagnosed with rheumatoid
arthritis and two with Parkinson’s disease.
Back pain (4 patients), cramps and muscle
pain (12 patients) were frequently reported.
Forced vital capacity systematically
assessed in 20 patients, was reduced in 2,
requiring non-invasive ventilation after,
respectively, 16 and 18 years of disease
duration. ECG was performed in 14
patients. Three patients from the same
family had moderate left ventricular dys-
function, 10, 11 and 17 years after the first
symptoms. For the last patient, there was a
past history of myocardial infarct (MCI).
Severe progressive FTD or MCI was
observed in 14 of 29 patients (48.2%); in
5 patients, data were not available. PDB
was confirmed in eight patients, and five
other reported bone pain. In three cases,
despite normal X-rays, bone alkaline phos-
phatase serum levels were high.
Serum creatine kinase (CK) levels were
measured in 19 of 40 patients. In 13 patients
(68.4%), CK levels were mildly raised with a
mean value of 379.6±142.1 U/L (N=0–
150), and a range between 162 and 725 U/
L. Neurophysiological data were available
for 19 of 39 patients. Myopathic changes
were reported in 10 of these patients, 5 pre-
sented a neurogenic pattern and 4 patients, a
mixed myopathic and neurogenic pattern.
Figure 1 Patient 6 illustrates a pseudo-FSHD pattern. Note the scapular involvement (A) and pronounced scapular winging (B). Patient 21: note
the wasting of the forearm and thenar eminence (C). Muscle MRI of pelvic girdle (D), thigh (E) and lower leg (F), showing mild fatty infiltration of
Gluteus, more pronounced fatty infiltration of vastus lateralis, vastus medialis, adductor magnus and sartorius.
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Muscle biopsies, available for 17 patients,
showed mild, unspecific myopathic changes
except for 1, which showed a dystrophic
pattern. Eleven biopsies (61%) revealed
rimmed vacuoles.
DISCUSSION
At present, only 43 families with VCP
mutations have been reported worldwide
to the Leiden Open Variation Database
(LVOD). Our data indicate a point preva-
lence of IBMPFD of 0.066/100 000 for
the UK population as a whole. Although
we accept that these figures need to be
interpreted with caution, and cases may
remain unrecognised, they suggest that
IBMPFD is a very rare disease. As our
department is a specialised service for
muscle diseases, it is not surprising that
muscle weakness was the first symptom in
the majority of patients; with either a
limb-girdle or combined proximal-distal
distribution. Distal weakness, mostly
affecting the small hand muscles, gener-
ally an extremely rare presentation of
myopathy, was identified in several
patients with IBMPFD.
Approximately half of our patients
remained ambulant after 17.8±7.5 years.
Dementia, or MCI, seems to correlate
with the severity of the disease, as 60% of
our patients with dementia or MCI were
non-ambulant, compared with 33.3% of
the patients without cognitive decline.
This data on rate of progression is similar
to previous reports.3
By comparison, the number of patients
with respiratory or cardiac insufficiency
was relatively low. They constitute the
main cause of death in IBMPFD,3 and
should be regularly monitored.
The presence of sphincter and erectile
dysfunction, and of Parkinson’s disease,
further expands the phenotypic character-
istics of IBMPFD. Parkinson’s disease has
recently been recognised as a clinical
manifestation of VCP-related disease.3 4
The presence of rimmed vacuoles,
although non-specific, remains the major
histological hallmark of IBMPFD.
The identification of mutations in differ-
ent exons emphasises that full gene
sequencing is required to exclude
VCP-related disease. Owing to multisystem
involvement, this disease should perhaps
be called VCP-related disease to try to
encompass the muscle, bone and central
nervous system manifestations.
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